NASDAQ:DVAX - Dynavax Technologies Stock Price, Forecast & News

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

Dynavax Technologies Co. (NASDAQ:DVAX) released its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by $0.10. The biopharmaceutical company had revenue of $10.58 million for the quarter, compared to analysts' expectations of $10.31 million. The company's quarterly revenue was up 624.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.65) earnings per share. View Dynavax Technologies' Earnings History.

Dynavax Technologies is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Dynavax Technologies.

5 brokerages have issued 12 month target prices for Dynavax Technologies' stock. Their forecasts range from $13.00 to $20.00. On average, they expect Dynavax Technologies' share price to reach $15.33 in the next year. This suggests a possible upside of 196.0% from the stock's current price. View Analyst Price Targets for Dynavax Technologies.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dynavax Technologies.

News stories about DVAX stock have trended somewhat positive on Monday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Dynavax Technologies earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Dynavax Technologies.

Some companies that are related to Dynavax Technologies include Amgen (AMGN), Celgene (CELG), Alexion Pharmaceuticals (ALXN), Alnylam Pharmaceuticals (ALNY), Arena Pharmaceuticals (ARNA), ArQule (ARQL), Achillion Pharmaceuticals (ACHN), Osiris Therapeutics (OSIR), SIGA Technologies (SIGA), AMAG Pharmaceuticals (AMAG), BioTime (BTX), AVEO Pharmaceuticals (AVEO), Vical (VICL), ImmunoCellular Therapeutics (IMUC) and Achieve Life Sciences (ACHV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Array Biopharma (ARRY), United Continental (UAL), Kite Pharma (KITE), Cara Therapeutics (CARA) and Micron Technology (MU).

Dynavax Technologies' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Chicago Capital LLC (4.77%), Senvest Management LLC (4.76%), Bain Capital Public Equity Management II LLC (4.24%), State Street Corp (4.11%), UBS Asset Management Americas Inc. (2.08%) and Blair William & Co. IL (2.01%). Company insiders that own Dynavax Technologies stock include David F Novack, David Louis Johnson, Francis Cano, Michael S Ostrach and Robert Coffman. View Institutional Ownership Trends for Dynavax Technologies.

DVAX stock was sold by a variety of institutional investors in the last quarter, including Senvest Management LLC, Point72 Asset Management L.P., Chicago Capital LLC, FMR LLC, DekaBank Deutsche Girozentrale, Rhenman & Partners Asset Management AB, Bank of America Corp DE and Gables Capital Management Inc.. Company insiders that have sold Dynavax Technologies company stock in the last year include David Louis Johnson, Michael S Ostrach and Robert Coffman. View Insider Buying and Selling for Dynavax Technologies.

DVAX stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Bain Capital Public Equity Management II LLC, Oxford Asset Management LLP, Rafferty Asset Management LLC, California Public Employees Retirement System, Alpine Global Management LLC, Blair William & Co. IL and Bank of New York Mellon Corp. View Insider Buying and Selling for Dynavax Technologies.

Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DVAX stock can currently be purchased for approximately $5.18.